Stunning presentation.
Looks like massive delays with the GBM trial. Reworking the whole design to include IV delivery for first dose and adding in chemo.
Disappointed we won't see any further GBM results for a long time (probably 2026), especially since the data to date has been so compelling.
CDH17 now officially the lead candidate. The cohort patient numbers are not at all clear. I take it 15 patients is all dose escalation. And then dose expansion - will they make up the phase 2 patient numbers?
Stunning presentation. Looks like massive delays with the GBM...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.068M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 13782293 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 17149687 | 17 |
View Market Depth
| Last trade - 16.21pm 02/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |
Day chart unavailable